Date: 2016-12-05
Type of information: Collaboration agreement
Compound: biological therapeutics including a biosimilar version of Mabthera®/Rituxan® - rituximab
Company: Sanofi (France) JHL Biotech (Taiwan)
Therapeutic area:
Type agreement: collaboration development commercialisation
Action mechanism:
Disease:
Details: * On December 5, 2016, Sanofi and JHL Biotech announced a strategic alliance to collaborate on the development and commercialization of biological therapeutics in China and with potential international expansion. JHL will lead the development, registration, and manufacturing activities while Sanofi will lead commercialization efforts in China. The collaboration brings together complementary capabilities of the two companies and represents a commitment to expanding patient access to affordable high quality modern therapies through local development of biologics in China.
Sanofi opened its first office in China in 1982. Its headquarters in Shanghai are supported by 11 branches in Beijing, Tianjin, Shenyang, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Jinan and Urumqi. As of 2015, Sanofi had more than 9,000 employees in China. The group has seven manufacturing facilities in China. These plants are located in Beijing, Hangzhou (two plants), Tangshan, Shenzhen,Nanchang and Nanjing.
JHL Biotech is a biopharmaceutical company with development and manufacturing facilities in Wuhan and Taiwan. The company is focused on research and development of new protein-based therapies and biosimilars.
Financial terms: Under the agreement, Sanofi will invest $80 million in newly issued JHL shares at NT$90 per share. In addition, Sanofi will make an upfront payment of $21 million to acquire exclusive rights for the proposed biosimilar of Rituximab and options to certain JHL pipeline products. JHL is entitled to receive milestones of up to $236 million and sales royalties.
Latest news:
